NEODECADRON Drug Patent Profile
✉ Email this page to a colleague
When do Neodecadron patents expire, and when can generic versions of Neodecadron launch?
Neodecadron is a drug marketed by Merck and is included in two NDAs.
The generic ingredient in NEODECADRON is dexamethasone sodium phosphate; neomycin sulfate. There are thirty-nine drug master file entries for this compound. Additional details are available on the dexamethasone sodium phosphate; neomycin sulfate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NEODECADRON?
- What are the global sales for NEODECADRON?
- What is Average Wholesale Price for NEODECADRON?
Summary for NEODECADRON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 37 |
| Patent Applications: | 2,581 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | NEODECADRON at DailyMed |
US Patents and Regulatory Information for NEODECADRON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | NEODECADRON | dexamethasone sodium phosphate; neomycin sulfate | OINTMENT;OPHTHALMIC | 050324-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Merck | NEODECADRON | dexamethasone sodium phosphate; neomycin sulfate | SOLUTION/DROPS;OPHTHALMIC | 050322-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
